Morphic Holding Stock Price, News & Analysis

Morphic Therapeutic (Nasdaq: MORF) has announced a conference call and webcast to discuss its fiscal year 2020 financial results and operational milestones, along with interim data from the MORF-057 Phase 1 clinical trial.

The event is scheduled for March 1, 2021, at 8:00 a.m. Eastern Time. MORF-057 is a selective oral inhibitor focusing on inflammatory bowel disease. Interested parties can access the event via the company's website.

Morphic Therapeutic (Nasdaq: MORF) announced that its CEO, Praveen Tipirneni, M.D., will participate in a panel discussion about the gastrointestinal microbiome at the 41st Annual Cowen Health Care Conference on March 2, 2021, at 11:10 AM ET. The discussion will be accessible via a live webcast on the company's investor website, with an archived replay available afterward. Morphic Therapeutic focuses on developing oral integrin therapies for serious chronic diseases, employing its proprietary Morphic Integrin Technology (MInT) Platform in collaboration with industry leaders.

Morphic Therapeutic (Nasdaq: MORF) has announced an expansion of its collaboration with Janssen Pharmaceuticals, initiating work on a third integrin target with activating antibodies. This partnership, facilitated by Johnson & Johnson Innovation, underlines Morphic's commitment to developing innovative integrin-targeted therapies for serious chronic diseases. Morphic will receive a milestone payment for this initiative, with additional product candidates subject to milestones and royalties.

Integrins play a crucial role in various cellular processes, impacting numerous diseases, aligning with Morphic's research scope.

Morphic Therapeutic (Nasdaq: MORF) announced that its CEO, Praveen Tipirneni, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 4:30 PM ET. A live webcast of the presentation will be available on the investor section of the company's website. Morphic is focused on developing oral integrin therapies for serious chronic conditions, including autoimmune and cardiovascular diseases, using its proprietary MInT technology platform. The company collaborates with prominent partners like AbbVie and Janssen.

Morphic Therapeutic (Nasdaq: MORF) has appointed Dr. Martin W. Edwards to its Board of Directors. Dr. Edwards brings extensive drug development experience, having recently retired as a Senior Partner at Novo Ventures. His expertise is expected to support Morphic as it advances its pipeline of integrin-targeted drug candidates, particularly with MORF-057 currently in phase 1 trials. Notably, the company utilizes its proprietary MInT technology platform to create oral therapeutics for various serious chronic diseases.

Morphic Therapeutic (NASDAQ: MORF) has announced its participation in the Jefferies Virtual London Healthcare Conference, with a presentation scheduled for November 18, 2020, at 2:55 PM ET. The event will feature insights into Morphic's innovative oral therapies targeting integrins for serious chronic diseases. Investors can access a live webcast of the presentation on the company’s website, with an archived replay available afterward. Morphic Therapeutic is advancing its pipeline using its proprietary MInT technology platform, in collaboration with AbbVie, Janssen, and Schrödinger.

Morphic Therapeutic (MORF) reported significant advancements in Q3 2020, including initiating a phase 1 clinical trial for MORF-057, targeting inflammatory bowel disease. The trial aims to assess safety and pharmacokinetics in healthy volunteers, with initial results expected in early 2021. Morphic received $20 million from AbbVie for licensing its αvβ6 integrin inhibitor program. Q3 revenue surged to $25.8 million, up from $5.7 million YoY, with a net income of $5.4 million. Research and development expenses rose to $16 million, reflecting ongoing clinical programs. Cash reserves stand at $213.1 million.

Morphic Therapeutic (NASDAQ: MORF) announced new preclinical data for MORF-057, a small molecule inhibitor of the integrin α4β7 for treating inflammatory bowel disease (IBD). These findings were presented at UEG Week Virtual 2020 and validate a new assay for measuring receptor occupancy in human blood. MORF-057 aims to block lymphocyte migration to intestinal tissues, with initial focus on ulcerative colitis. The company emphasizes its commitment to translating these promising preclinical outcomes into clinical results as part of its Phase 1 trial.

Morphic Therapeutic has announced the initiation of a Phase 1 clinical trial for MORF-057, the first integrin inhibitor developed from its MInT Platform. This oral small molecule targets the α4β7 integrin for treating inflammatory bowel disease (IBD), specifically ulcerative colitis. The trial aims to evaluate the safety, pharmacokinetics, and receptor occupancy of MORF-057 in healthy volunteers, with results expected to provide key insights into its effectiveness as a novel treatment option.